Drug Design: Methodology, concepts, and mode-of-action

Drug Design: Methodology, Concepts, and Mode-of-Action

Volumn , Issue , 2013, Pages 1-901

  Klebe, Gerhard ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84929283700     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-17907-5     Document Type: Book

References (489)

1. Barondes SH (1993) Molecules and mental illness, Scientific American Library. W. H. Freeman and Company, New York.
2. Beddell CR (ed) (1992) The design of drugs to macromolecular targets. Wiley, Chichester.
3. Fischer D, Breitenbach J (eds) (2003) Die Pharmaindustrie. Spektrum Akademischer Verlag, Heidelberg/Berlin.
4. Friedrich C, Müller-Jahncke W-D (2005) Von der Frühen Neuzeit bis zur Gegenwart, vol 2. GOVI-Verlag, Eschborn.
5. Higby G (ed) (1997) The inside story of medicine. A Symposium. Madison, Wi.
6. Herrmann EC, Franke R (eds) (1995) Computer-aided drug design in industrial research, Ernst Schering research foundation workshop 15. Springer, Berlin.
7. Müller K (ed) (1995) De Novo Design, Persp. Drug Discov. Design, vol 3, Escom, Leiden, 1995.
8. MüllerJahnke WD, Friedrich C (2005) Arzneimittelgeschichte. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
9. Perun TJ, Propst CL (eds) (1989) Computer-aided drug design. Methods and applications. Marcel Dekker, New York.
10. Porter R, Teich M (eds) (1995) Drugs and narcotics in history. Cambridge.
11. Restak RM (1994) Receptors. Bantam Books, New York.
12. Schmitz R (1998) Geschichte der Pharmazie, vol 1. GOVI-Verlag, Eschborn.
13. Verband Forschender Arzneimittelhersteller (2009) e.V.: Http://www.vfa.de/de/presse/statcharts/arzneimittelmarkt/. Accessed 22 Nov 2011.
14. Werth B (1994) The Billion-Dollar Molecule. One Company's Quest for the Perfect Drug. Touchstone, New York.
15. Beddell CR, Goodford PJ, Norrington FE et al (1976) Compounds designed to fit a site of known structure in human hemoglobin. Br J Pharmac 57:201-209.
16. Breggin PR, Breggin GR (1994) Talking back to prozac. St. Martin's Press, New York.
17. Kramer P (1993) Listening to prozac. Viking, New York.
18. Mutschler E (1987) Arzneimittel - Erfolge, Misserfolge, Hoffnungen. Deutsche Apoth-Ztg 127:2025-2033.
19. Newman DJ, Cragg GM (2007) Natural products as sources of new drugs over the last 25 years. J Nat Prod 70:461-477.
20. Noe CR, Bader A (1993) Facts are better than dreams. Chem Brit 29:126-128, Kekulés and Loschmidts Formeln.
21. Ban TA (2006) The role of serendipity in drug discovery. Dialogues Clin Neurosci 8:335-344.
22. Burger A (1983) A guide to the chemical basis of drug design. Wiley, New York.
23. de Stevens G (1986) Serendipity and structured research in drug discovery. Fortschr Arzneimittelforsch 30:189-203.
24. Kubinyi H (1999) Chance favors the prepared mind. From serendipity to rational drug design. J Receptor Signal Transd Res 19:15-39.
25. Restak RM (1994) Receptors. Bantam Books, New York.
26. Roberts RM (1989) Serendipity. Accidental discoveries in science. Wiley, New York.
27. Sneader W (1990) Chronology of drug introductions. In: Hansch C, Sammes PG, Taylor JB (eds) Comprehensive medicinal chemistry, vol 1, Kennewell PD (ed). Pergamon Press, Oxford, S.7-S.80.
28. Cahn A, Hepp P (1886) Das Antifebrin, ein neues Fiebermittel. Centralblatt für Klinische Medizin 7:561-564.
29. Hofmann A (1993) LSD - mein Sorgenkind, dtv/Klett-Cotta.
30. Sternbach LH (1978) The Benzodiazepine story. Fortschr Arzneimittelforsch 22:229-266.
31. Stütz A (1987) Allylamine derivatives - A new class of active substances in antifungal chemotherapy. Angew Chem Int Ed 26:320-328.
32. von Vámossy Z (1900) Ist Phenolphthalein ein unschädliches Mittel zum Kenntlichmachen von Tresterweinen? Chemiker-Zeitung 24:679-680.
33. Burger A (1983) A guide to the chemical basis of drug design. Wiley, New York.
34. Ryan J, Newman A, Jacobs M (eds) (2000) The pharmaceutical century. Ten decades of drug discovery. American Chemical Society, Washington, DC, Supplement to ACS Publications.
35. Sneader W (1996) Drug prototypes and their exploitation. Wiley, Chichester.
36. Sneader W (2005) Drug discovery. A history. Wiley, Chichester.
37. Verg E (1988) Meilensteine: 125 Jahre Bayer, 1863-1988. Bayer AG, Leverkusen.
38. Aspirin - eine unendliche Geschichte, Research. Das Bayer-Forschungsmagazin, Issue 6, S. 4-21 (1992) and other articles in this magazine.
39. Battistini B, Botting R, Bakhle YS (1994) COX-1 and COX-2: Toward the development of more selective NSAIDs. Drug News Perspect 7:501-512.
40. Kelce WR et al (1995) Persistent DDT Metabolite p, p'-DDE is a potent androgen receptor antagonist. Nature 375:581-585.
41. Patrono C (1989) Aspirin and human platelets: from clinical trials to acetylation of cyclooxygenase and back. Trends Pharm Sci 10:453-458.
42. Schlitzer M (2007) Malaria chemotherapeutics part I: History of antimalarial drug development, currently used therapeutics, and drugs in clinical development. Chem Med Chem 2:944-986.
43. Wiesner J, Ortmann R, Jomaa H, Schlitzer M(2003) New antimalarial drugs. Angew Chem Int Ed Engl 42:5274-5293.
44. Andrews PR (1993) Drug-receptor interactions. In: Kubinyi H (ed) 3D-QSAR in drug design. Theory, methods and applications. Escom, Leiden, pp 13-40.
45. Andrews PR, Craik DJ, Martin JL (1984) Functional group contributions to drug-receptor interactions. J Med Chem 27:1648-1657.
46. Böhm HJ, Klebe G (1996) What can we learn from molecular recognition in protein-ligand complexes for the design of new drugs? Angew Chem Int Ed Engl 35:2588-2614.
47. Böhm H-J, Schneider G (2003) Protein-ligand interactions. From molecular recognition to drug design. In: Mannhold R, Mannhold R, Kubinyi H, Folkers G (eds) Methods and principles in medicinal chemistry. Wiley-VCH, Weinheim.
48. Creighton TE (1992) Proteins: Structures and molecular properties, 2nd edn. W.H. Freeman, New York.
49. Gohlke H, Klebe G (2002) Approaches to the description and prediction of binding affinity of small-molecule ligands to macromolecular receptors. Angew Chem Int Ed Engl 41:2644-2676.
50. Kuntz ID, Chen K, Sharp KA, Kollman PA (1999) The maximal affinity of ligands. Proc Natl Acad Sci USA 96:9997-10002.
51. Ehrlich P (1913) Chemotherapeutics: Scientific principles, methods and results. Lancet 182:445-451.
52. Fersht AR, Shi JP, Knill-Jones J et al (1985) Hydrogen bonding and biological specificity analysed by protein engineering. Nature 314:235-238.
53. Gerlach C, Smolinski M et al (2007) Thermodynamic inhibition profile of a cyclopentyl- And a cyclohexyl derivative towards thrombin: The same, but for deviating reasons. Angew Chem Int Ed Engl 46:8511-8514.
54. Lichtenthaler FW (1994) 100 Years "Schluessel-Schloss-Prinzip": What made Emil Fischer use this analogy? Angew Chem Int Ed Engl 33:2364-2374.
55. Mason RP, Rhodes DG, Herbette LG (1991) Reevaluating equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes. J Med Chem 34:869-877.
56. Morgan BP, Scholtz JM, Ballinger MD, Zipkin ID, Bartlett PA (1991) Differential binding energy: A detailed evaluation of the influence of hydrogen-bonding and hydrophobic groups on the inhibition of thermolysin by phosphorous-containing inhibitors. J Am Chem Soc 113:297-307.
57. Petrova T, Steuber H et al (2005) Factorizing selectivity determinants of inhibitor binding toward aldose and aldehyde reductases: Structural and thermodynamic properties of the aldose reductase mutant Leu300Pro-Fidarestat complex. J Med Chem 48:5659-5665.
58. Ariëns EJ, Soudijn W, Timmermans PBMWM (1983) Stereochemistry and biological activity of drugs. Blackwell Scientific, Oxford.
59. Brown C (ed) (1990) Chirality in drug design and synthesis. Academic, London.
60. Caner H, Groner E, Levy L (2004) Trends in the development of chiral drugs. Drug Discov Today 9:105-110.
61. Eichelbaum M, Testa B, Somogyi A (2002) Handbook of experimental pharmacology, stereochemical aspects of drug action and disposition. Springer, Heidelberg.
62. Holmstedt B, Frank H, Testa B (1990) Chirality and biological activity. Alan R. Liss, New York.
63. Klebe G (2004) Differences in binding of stereoisomers to protein active sites. In: Pifat-Mrzljak G (ed) Supramolecular structure and function 8. Kluwer Academic/Plenum, New York, pp 31-53.
64. Smith DF (ed) (1989) CRC handbook of stereoisomers: Therapeutic drugs. CRC Press, Boca Raton.
65. Ariëns EJ (1984) Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology. Eur J Clin Pharmacol 26:663-668.
66. Ariëns EJ (1993) Nonchiral, homochiral and composite chiral drugs. Trends Pharmacol Sci 14:68-75.
67. Ariëns EJ et al (1976) Stereoselectivity and affinity in molecular pharmacology. Fortschr Arzneimittelforsch 20:101-142.
68. Bocola M, Stubbs MT, Sotriffer C, Hauer B, Friedrich T, Dittrich K, Klebe G (2003) Structural and energetic determinants for enantiopreferences in kinetic resolution of lipases. Protein Eng 16:319-322.
69. Greer J, Erickson JW, Baldwin JJ, Varney MD (1994) Application of the three-dimensional structures of protein target molecules in structure-based drug design. J Med Chem 37:1035-1054.
70. Jung G (1992) Proteins from the D-chiral world. Angew Chem Int Ed Engl 31:1457-1459.
71. Klaholz BP, Mitschler A, Belema M, Zusi C, Moras D (2002) Enantiomer discrimination illustrated by high-resolution crystal structures of the human nuclear receptor hRARg. Proc Natl Acad Sci USA 97:6322-6327.
72. Mason S (1986) The origin of chirality in nature. Trends Pharmacol Sci 7: 20-23, and other articles from the same author on pp. 60-64, 112-116, 155-158, 200-205, 227-230 and 281-285.
73. Stinson SC (1994) Chiral drugs. Chem Eng News S. 38-72, and 9 Oct 1995, S. 44-74.
74. Stubbs MT, Huber R, Bode W(1995) Crystal structures of factor Xa-specific Inhibitors in complex with Trypsin: Structural grounds for inhibition of factor Xa and selectivity against thrombin. FEBS Lett 375:103-107.
75. Burger A (1983) A guide to the chemical basis of drug design. Wiley, New York.
76. Sneader W (1990) Chronology of drug introductions. In: Hansch C, Sammes PG, Taylor JB (eds) Comprehensive medicinal chemistry. vol 1, Kennewell PD (ed). Pergamon, Oxford, pp 7-80.
77. Verg E (1988) Meilensteine. 125 Jahre Bayer 1863-1988. Bayer AG, Leverkusen.
78. Badio B et al (1994) Epibatidine: discovery and definition as a potent analgesic and nicotinic agonist. Med Chem Res 4:440-448 and other works (Special journal edition dedicated to Epibatidine).
79. Buss AD, Waigh RD (1995) Natural products as leads for new pharmaceuticals. In: Wolff M (ed) Burger's medicinal chemistry and drug discovery. Wiley, New York, pp 983-1033.
80. Hylands PJ, Nisbet LJ (1991) The search for molecular diversity (I): Natural products. Ann Rep Med Chem 26:259-269.
81. Pettit GR et al (1993) Isolation of dolastatins 10-15 from the marine mollusc Dolabella Auricularia. Tetrahedron 41:9151-9170.
82. Suffness M (1993) Taxol: from discovery to therapeutic use. Ann Rep Med Chem 28:305-314.
83. Tempesta MS, King SR (1994) Ethnobotany as a source for new drugs. Ann Rep Med Chem 29:325-330.
84. Blundell TL, Jhoti H, Abell C (2002) High-throughput crystallography for lead discovery in drug design. Nat Rev Drug Discov 1:45-54.
85. Hajduk PJ, Greer J (2007) A decade of fragment-based drug design: Strategic advances and lessons learned. Nat Rev Drug Discov 6:211-219.
86. Jahnke W, Erlanson DA (2006) Fragment-based approaches in drug discovery. In: Mannhold R, Kubinyi H, Folkers G (eds) Methods and principles in medicinal chemistry, vol 34. Wiley- VCH, Weinheim.
87. Jones AK, Buckingham SD, Sattelle DB (2005) Chemistry-to-gene screens in Caenorhabitis elegans. Nat Rev Drug Discov 4:321-330.
88. Klebe G (2006) Virtual ligand screening: Strategies, perspectives and limitations. Drug Discov Today 11:580-592.
89. Löfas S (2004) Optimizing the hit-to-lead process using SPR analysis. Assay Drug Dev Technol 2:407-415.
90. Siegel MM (2002) Early discovery drug screening using mass spectrometry. Curr Topics Med Chem 2:13-33.
91. Sotriffer C (2010) Virtual screening. In: Mannhold R, Kubinyi H, Folkers G (eds) Methods and principles in medicinal chemistry, vol 48. Wiley-VCH, Weinheim.
92. Vogtherr M, Fiebig K (2003) NMR-based screening methods for lead discovery. In: Hillisch A, Hilgenfeld R (eds) Modern methods of drug discovery. Birkhäusen Verlag, Boston, pp S183- S120. ISBN 376436081X.
93. Hajduk PJ, Sheppard G, Nettesheim DG, Olejniczak ET, Shuker SB, Meadows RP, Steinman DH, Carrera GM Jr, Marcotte PA, Severin J, Walter K, Smith H, Gubbins E, Simmer R, Holzman TF, Morgan DW, Davidsen SK, Summers JB, Fesik SW (1997) Discovery of potent nonpeptide inhibitors of stromelysin using SAR by NMR. J Am Chem Soc 119:5818-5827.
94. Erlanson DA, Braisted AC, Raphael DR, Randal M, Stroud RM, Gordon EM, Wells JA (2000) Site-directed ligand discovery. Proc Natl Assoc Soc 97:9367-9372.
95. Sneader W (1985) Drug discovery: The evolution of modern medicines. Wiley, New York.
96. Taylor JB, Triggle DJ (eds) (2007) Comprehensive medicinal chemistry II. Elsevier, Oxford.
97. Wermuth CG (ed) (2008) The practice of medicinal chemistry, 3rd edn. Elsevier-Academic, New York.
98. Burger A (1991) Isosterism and bioisosterism in drug design. Fortschr Arzneimittelforsch 37:287-371.
99. Copeland RA, Pompliano DL, Meek TD (2006) Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov 5:730-740.
100. Fokkens J, Klebe G (2006) A simple protocol to estimate protein binding affinity differences for enantiomers without prior resolution of racemates. Angew Int Ed Engl 45:985-989.
101. Hansch C (1974) Bioisosterism. Intra-Science Chem Rept 8:17-25.
102. Lipinski CA (1986) Bioisosterism in drug design. Ann Rep Med Chem 21:283-291.
103. Ohtaka H, Freire E (2005) Adaptive inhibitors of the HIV-1 protease. Prog Biophys Mol Biol 88:193-208.
104. Shuman CF, Markgren P-O, Hämäläinen M, Danielson UH (2003) Elucidation of HIV-1 protease resistance by characterization of interaction kinetics between inhibitors and enzyme variants. Antiviral Res 58:235-242.
105. Steuber H, Heine A, Klebe G (2007) Structural and thermodynamic study on aldose reductase: Nitro-substituted inhibitors with strong enthalpic binding contribution. J Mol Biol 368:618-638.
106. Thornber CW (1979) Isosterism and molecular modification in drug design. Chem Soc Rev 8:563-580.
107. Balant LP, Doelker E (1995) Metabolic considerations in prodrug design. In: Wolff ME (ed) Burger's medicinal chemistry, vol I, 5th edn. Wiley, New York, pp 949-982.
108. Bodor N (1987) Prodrugs and site-specific chemical delivery systems. Annu Rep Med Chem 22:303-313.
109. Bundgaard H (ed) (1985) Design of prodrugs. Elsevier, Amsterdam.
110. Bundgaard H (1991) Design and application of prodrugs. In: Krogsgaard-Larsen P, Bundgaard H (eds) A textbook of drug design and development. Harwood Academic, Chur, pp 113-191.
111. Ettmayer P, Amidou GL, Clement B, Testa B (2004) Learned from marketed and investigational prodrugs. J Med Chem 47:2394-2404.
112. Gibson GG (1994) Introduction to drug metabolism. Blackie, London.
113. Rautio J (2012) Prodrugs and targeted delivery-towards better ADME properties. In: Mannhold R, Kubinyi H, Folkers G (eds) Methods and principles in medicinal chemistry, vol 47. Wiley-VCH, Weinheim.
114. Silverman RB (2004) The organic chemistry of drug design and drug action, 2 edn. Elsevier Academic, Oxford, Chapter 7, Drug metabolism, and Chapter 8, Prodrugs and drug delivery Systems.
115. Stella VJ, Borchardt RT, Hageman MJ, Oliyai R, Maag H, Tilley JW (eds) (2007) Prodrugs: challenges and rewards, vol 2. Springer, New York.
116. Testa B (2007) Prodrug and soft drug design. In: Taylor JB, Triggle DJ (eds) Comprehensive medicinal chemistry II, vol 5. Elsevier, Oxford, pp 1009-1041.
117. Testa B, Mayer JM (2003) Hydrolysis in drug and prodrug metabolism - chemistry, biochemistry and enzymology. Wiley-VHCA, Zürich.
118. Bodor N, Buchwald P (2005) Ophthalmic drug design based on the metabolic activity of the eye: Soft drugs and chemical delivery systems. AAPS J 7:E820-E833.
119. Brewster ME, Pop E, Bodor N (1993) Chemical approaches to brain-targeting of biologically active compounds. In: Kozikowski AP (ed) Drug design for neuroscience. Raven, New York.
120. Napier MP, Sharma SK et al (2000) Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma. Clin Cancer Res 6:765-772.
121. Ahn J-M, Boyle NA, MacDonald MT, Janda KD (2002) Peptidomimetics and peptide backbone modifications. Mini Rev Med Chem 2:463-473.
122. Gante J (1994) Peptidomimetics-tailored enzyme inhibitors. Angew Chem Int Ed Engl 33:1699-1701.
123. Giannis A, Kolter T (1993) Peptidomimetics for receptor ligands-discovery, development, and medical perspectives. Angew Chem Int Ed Engl 32:1244-1267.
124. Hirschmann R (1991) Medicinal chemistry in the golden age of biology: lessons from steroid and peptide research. Angew Chem Int Ed Engl 30:1278-1301.
125. Marahiel MA (2009) Working outside the protein-synthesis rules: Insights into non-ribosomal peptide synthesis. J Pept Sci 15:799-807.
126. Howson W (1995) Rational design of Tachykinin receptor antagonists. Drug News Perspect 8:97-103.
127. Lauri G, Bartlett PA (1994) CAVEAT: A program to facilitate the design of organic molecules. J Comput Aided Mol Des 8:51-66.
128. Lelais G, Seebach D (2004) β2-amino acids-synthesis, occurrence in natural products, and components of β-peptides. Biopolymers 76:206-243.
129. McLeod AM, Merchant KJ, Cascieri MA et al (1993) N-Acyl-Ltryptophan benzyl esters: potent substance P receptor antagonists. J Med Chem 36:2044-2045.
130. Merchant KJ, Lewis RT, MacLeod AM (1994) Synthesis of homochiral ketones derived from L-tryptophan: potent substance P receptor antagonists. Tetrahedron Lett 35:4205-4208.
131. Olson GL, Bolin DR, Bonner MP et al (1993) Concepts and progress in the development of peptide mimetics. J Med Chem 36:3039-3049.
132. Balkenhohl F, von dem Bussche-Hünnefeld C, Lansky A, Zechel C (1996) Combinatorial synthesis of small organic molecules. Angew Chem Int Ed Engl 35:2288-2337.
133. Bannwarth W, Hinzen B (2006) Combinatorial chemistry. From theory to application. In: Mannhold R, Kubinyi H (eds) Methods and principles in medicinal chemistry, 26th edn. Wiley-VCH, Weinheim.
134. Baum RM (1994) Combinatorial approaches provide fresh leads for medicinal chemistry. Chem Eng News 72:20-26.
135. Beck-Sickinger AG, Weber P (2002) Combinatorial strategies in biology and chemistry. Wiley, Weinheim.
136. Bunin BA (1998) The combinatorial index. Academic, San Diego.
137. Gallop MA, Barrett RW, Dower WJ, Fodor SPA, Gordon EM (1994) Applications of combinatorial technologies to drug discovery. 1. Background and peptide combinatorial libraries. J Med Chem 37:1233-1251.
138. Gordon EM, Barrett RW, Dower WJ, Fodor SPA, Gallop MA (1994) Applications of combinatorial technologies to drug discovery. 2. Combinatorial organic synthesis, library screening strategies, and future directions. J Med Chem 37:1385-1401.
139. Jung G (1999) Combinatorial chemistry. Wiley-VCH, Weinheim.
140. Jung G, Beck-Sickinger AG (1992) Multiple peptide synthesis methods and their applications. New synthetic methods. Angew Chem Int Ed Engl 31:367-383.
141. Kay BK (1994) Biologically displayed random peptides as reagents in mapping protein-protein interactions. Persp Drug Discov Design 2:251-268.
142. Kolb HC, Finn MG, Barry Sharpless K (2001) Click chemistry: diverse chemical function from a few good reactions. Angew Chem Int Ed Engl 40:2004-2021.
143. Ley SV, Baxendale IR (2002) New tools and concepts for modern organic synthesis. Nat Rev Drug Discov 1:573-586.
144. Madden D, Krchnak V, Lebl M (1994) Synthetic combinatorial libraries: views on techniques and their application. Persp Drug Discov Design 2:269-285.
145. Moos WH, Green GD, Pavia MR (1993) Recent advances in the generation of molecular diversity. Annu Rep Med Chem 28:315-324.
146. Nicolaou KC, Hanko R, Hartwig W (2002) Handbook of combinatorial chemistry. Drugs, catalysts, materials. Wiley-VCH, Weinheim.
147. Ramström O, Lehn J-M (2002) Drug discovery by dynamic combinatorial libraries. Nat Rev Drug Discov 1:27-36.
148. Seneci P (2000) Solid-phase synthesis and combinatorial technologies. Wiley-Interscience, New York.
149. Bourne Y, Kolb HC, Radic Z, Sharpless KB, Taylor P, Marchot P (2004) Freeze-frame inhibitor captures acetylcholinesterase in a unique conformation. Proc Natl Acad Sci 110:1449-1454.
150. Carell T, Wintner EA, Sutherland AJ, Rebek J, Dunayevskiy YM, Vouros P (1995) New promise in combinatorial chemistry: Synthesis, characterization, in screening of small-molecule libraries in solution. Chem Biol 2:171-183.
151. Dooley CT, Chung NN, Schiller PW, Houghton RA (1993) Acetalins: Opioid receptor antagonists determined through the use of synthetic peptide combinatorial libraries. Proc Natl Acad Sci USA 90:10811-10815.
152. Fink T, Reymond J-L (2007) Virtual exploration of the chemical universe up to 11 atoms of C, N, O, F: Assembly of 26.4 million structures (110.9 million stereoisomers) and analysis for new ring systems, stereochemistry, physicochemical properties, compound classes, and drug discovery. J Chem Inf Model 47:342-353.
153. Geysen HM, Meloen R, Barteling S (1984) Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid. Proc Natl Acad Sci USA 81:3998-4002.
154. Murphy MM, Schullek JR, Gordon EM, Gallop MA (1995) Combinatorial organic synthesis of highly functionalized pyrrolidines: Identification of a potent angiotensin converting enzyme inhibitor from a mercaptoracyl proline library. J Am Chem Soc 117:7029-7030.
155. Zuckermann RN, Martin EJ, Spellmeyer DC et al (1994) Discovery of nanomolar ligands for 7-transmembrane G-protein- coupled receptors from a diverse N-(substituted)glycine peptoid library. J Med Chem 37:2678-2685.
156. Cooper NG (ed) (1994) The human genome project. Deciphering the blueprint of heredity. University Science, Mill Valley.
157. Kiely JS (1994) Recent advances in antisense technology. Ann Rep Med Chem 29:297-306.
158. Lander ES et al (2001) Initial sequencing and analysis of the human genome. Nature 409:860-921.
159. Monastersky GM, Robel JM (eds) (1995) Strategies in transgenic animal science. Blackwell Science, Oxford.
160. Mullis KB, Ferré F, Gibbs RA (eds) (1994) The polymerase chain reaction. Birkhäuser, Boston.
161. Pandit SB, Balaji S, Srinivasan N (2004) Structural and functional characterization of gene products encoded in the human genome by homology detection. IUBMB Life 56:317-331.
162. Post LE (1995) Gene therapy: progress, new directions, and issues. Ann RepMed Chem 30:219-226.
163. Slagboom PE, Meulenbelt I (2002) Organisation of the human genome and our tools for identifying disease genes. Biol Psychol 61:11-31.
164. Venter JC et al (2001) The sequence of the human genome. Science 291:1304-1351.
165. Wolff JA (1994) Gene therapeutics. Methods and applications of direct gene transfer. Birkhäuser, Boston.
166. Adams MD et al (1995) Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence. Nature 377(Suppl 6547):3-174 (85 authors including JC Venter).
167. Carlton JM et al (2007) Draft genome sequence of the sexually transmitted pathogen Trichomonas vaginalis. Science 315:207-212.
168. Chang MW, Barr E, Seltzer J, Jiang Y-Q, Nabel GJ, Nabel EG, Parmacek MS, Leiden JM (1995) Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science 267:518-522.
169. Craig C (1995) Bristol-Myers to Pay $2.7M for transgenic goats that make human antibodies. BioWorld Today 6:1.
170. Explore the Homo sapiens genome. http://www.ensembl.org/Homo-sapiens/index.html.
171. Fleischmann RD et al (JC Venter et al) (1995) Whole genome random sequencing and assembly of Haemophilus influenzae Rd. Science 269:496-512.
172. Human genome database with functional predictions.
173. Schneiker S et al (2007) Complete genome sequence of the Myxobacterium Sorangium cellulosum. Nat Biotech 25:1281-1289.
174. Seide RK, Giaccio A (1995) Patenting animals. Chem Ind 16:656-659.
175. Sippl W, Jung M (2009) Epigenetic targets in drug discovery methods and principles in medicinal chemistry. In: Mannhold R, Kubinyi H, Folkers G (eds) Methods and principles in medicinal chemistry, vol 42. Wiley-VCH, Weinheim.
176. Blundell TL, Johnson LN (1976) Protein crystallography. Academic, London.
177. Drenth J (1994) Principles of protein X-ray crystallography. Springer, Berlin.
178. Dunitz JD (1979) X-ray analysis and the structure of organic molecules. Cornell University Press, Ithaca.
179. Friebolin H (2010) Basic one- And two-dimensional nmr spectroscopy. Wiley-VCH, Weinheim.
180. Glusker JP, Trueblood KN (1985) Crystal structure analysis, a primer, 2nd edn. Oxford University Press, New York.
181. Glusker JP, Lewis M, Rossi M (1994) Crystal structure analysis for chemists and biologists. VCH Publishers, New York.
182. Pellecchia M, Bertini I, Cowburn D et al (2008) Perspectives on NMR in drug discovery: A technique comes of age. Nature Rev Drug Discov 7:738-745.
183. Wuthrich K (1986) NMR of proteins and nucleic acids. Wiley, New York DeRosier DJ (1993) Turn-of-the-century electron microscopy. Curr Biol 3:690-692.
184. Wear MA, Kan D, Rabu A, Walkinshaw MD (2007) Experimental determination of van der Waals energies in a biological system. Angew Chem Int Ed 46:6453-6456.
185. Branden C, Tooze J (1999) Introduction to protein structure, 2nd edn. Garland, New York.
186. Bürgi HB, Dunitz JD (1994) Structure correlation, vol 1. VCH, Weinheim.
187. Jeffrey GA, Saenger W (1991) Hydrogen bonding in biological structures. Springer, Berlin.
188. Schulz GE, Schirmer RH (1978) Principles of protein structure. Springer, New York.
189. Allen FA, Kennard O, Taylor R (1983) Systematic analysis of structural data as a research technique in organic chemistry. Acc Chem Res 16:146-153.
190. CSD Database: Www.ccdc.cam.ac.uk/products/csd/.
191. Klebe G (1994) The use of composite crystal-field environments in molecular recognition and the de novo design of protein ligands. J Mol Biol 237:212-235.
192. Koch O, Klebe G (2008) Turns revisited: A uniform and comprehensive classification of normal, open, and reverse turn families minimizing unassigned random chain portions. Proteins: Struct Funct Bioinform 74:353-367.
193. Lario PI, Vrielink A (2003) Atomic resolution density maps reveal secondary structure dependent differences in electronic distribution. J Am Chem Soc 125:12787-12794.
194. Orengo CA, Jones DT, Thornton JM (1994) Protein superfamilies and domain superfolds. Nature 372:631-634.
195. PDB Database: Http://www.rcsb.org/pdb/home/home.do.
196. Vyas K, Monahar H, Venkatesan K (1990) Thermally induced O to N acyl migration in salicylamides. Thermal motion analysis of the reactants. J Phys Chem 94:6069-6073.
197. Wood VJL, Patterson AW et al (2005) Substrate activity screening: A fragment-based method for the rapid identification of nonpeptidic protease inhibitors. J Am Chem Soc 127:15521-15527.
198. Barnickel G (1995) Molecular modelling - von der Theorie zur Wirklichkeit. Chemie in unserer Zeit 29:176-185.
199. Birner P, Hofmann HJ, Weis C (1979) MO-theoretische Methoden in der organischen Chemie. Akademie-Verlag, Berlin.
200. Burkert U, Allinger NL (1982) Molecular mechanics, ACS monograph 177. American Chemical Society, Washington, DC.
201. Goodfellow JM (ed) (1995) Computer modelling in molecular biology. VCH, Weinheim.
202. Kunz RW (1991) Molecular modelling für Anwender, Teubner Studienbücher.
203. Leach A (2001) Molecular modelling: principles and applications, 2nd edn. Prentice Hall, New York.
204. Lipkowitz KB, Boyd DB (eds) (1990) Reviews in computational chemistry. VCH, Weinheim.
205. Cornell WD et al (1995) A Second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J Am Chem Soc 117:5179-5197.
206. Cram DJ (1988) The design of molecular hosts, guests, and their complexes. Angew Chem Int Ed Eng 27:1009-1020.
207. Fischer E (1922) Aus meinem Leben. Springer, Berlin, p 134.
208. Pullman B (1990) Molecular modelling, with or without quantum chemistry. In: Rivail JL (ed) Modelling of molecular structures and properties, vol 71, Studies in physical and theoretical chemistry. Elsevier, Amsterdam, pp 1-15.
209. van Gunsteren WF, Weiner PK (1989) Computer simulations of biomolecular systems. ESCOM, Leiden.
210. Watson JD (2010) The double helix, Phoenix, London; originally published by Weidenfeld & Nicholson 1968.
211. Leach A (2001) Molecular modelling: principles and applications, 2nd edn. Prentice Hall, Englewood Cliffs.
212. Böhm HJ, Klebe G (1996) What can we learn from molecular recognition in protein-ligand complexes for the design of new drugs? Angew Chem Intl Ed Eng 35:2588-2614.
213. Klebe G, Mietzner T (1994) A fast and efficient method to generate biologically relevant conformations. J Comput Aided Mol Design 8:583-606.
214. Klebe G (1994) Structure correlation and ligand/receptor interactions. In: Bürgi HB, Dunitz JD (eds) Structure correlation. VCH, Weinheim, pp 543-603.
215. Klebe G (1995) Toward a more efficient handling of conformational flexibility in computerassisted modelling of drug molecules. Persp Drug Des Discov 3:85-105.
216. Marshall GR, Naylor CB (1990) Use of molecular graphics for structural analysis of small molecules. In: Hansch C, Sammes PG, Taylor JB (eds) Comprehensive medicinal chemistry, 4. Pergamon, Oxford, pp 431-458.
217. Stegemann B, Klebe G (2011) Cofactor-binding sites in proteins of deviating sequence: Comparative analysis and clustering in torsion angle, cavity, and fold space. Proteins 80:626-648.
218. Klebe G (1993) Structural alignment of molecules. In: Kubinyi H (ed) 3D-QSAR in drug design, Theory, methods and application. ESCOM, Leiden, pp 173-199.
219. Langer T, Hoffmann RD (2006) Methods and principles in medicinal chemistry. In: Mannhold R, Kubinyi H, Folkers G (eds) Pharmacophores and pharmacophore searches, vol 32. Wiley-VCH, Weinheim.
220. Marshall GR (1989) Computer-aided drug design. In: Richards WG (ed) Computer-aided molecular design. IBC Technical Services, London, pp 91-104.
221. Bolin JT, Filman DJ, Matthews DA, Hamlin RC, Kraut J (1982) Crystal structure of Eschericha coli and Lactobacillus casei dihydrofolate reductase refined at 1.7 A resolution. J Biol Chem 257(13):13650-13662.
222. Kearsley SK, Smith GM (1990) An alternative method for the alignment of molecular structures: Maximizing electrostatic and steric overlap. Tetrahedron Comput Methodol 3:615-633.
223. Klebe G, Mietzner T, Weber F (1995) Different approaches toward an automatic structural alignment of drug molecules: Applications to sterol mimics, thrombin and thermolysin inhibitors. J Comput-Aided Mol Des 8:751-778.
224. Klunk WE, Kalman BL, Ferrendelli JA, Covey DF (1983) Computer-assisted modeling of the picrotoxinin and γ-butyrolactone receptor site. Mol Pharmacol 23:511-518.
225. Kuster DJ, Marshall GR (2005) Validated ligand mapping of ACE active site. J Comput-Aided Mol Des 19:609-615.
226. Mackay MF, Sadek M (1983) The crystal and molecular structure of picrotoxinin. Aust J Chem 36:2111-2117.
227. Marshall GR, Barry CD, Bossard HE, Dammkoehler RA, Dunn DA (1979) The conformational parameter in drug design: The active analog approach. In: Olson EC, Christoffersen RE (eds) Computer-assisted drug design, vol 112, ACS symposium series. American Chemical Society, Washington, DC, pp 205-226.
228. Martin YC (1992) 3D database searching in drug design. J Med Chem 35:2145-2154.
229. Mayer D, Naylor CB, Motoc I, Marshall GR (1987) A unique geometry of the active site of angiotensin-converting enzyme consistent with structure-activity studies. J Comput-Aided Mol Des 1:3-16.
230. Seidel W, Meyer H, Born L, Kazda S, Dompert W (1984) Rigid calcium antagonists of the Nifedipine-type: geometric requirements for the dihydropyridine receptor. In: Seydel JK (ed) QSAR as strategies in the design of bioactive compounds. VCH, Weinheim, pp 366-369.
231. Hansch C, Leo A (1995) Exploring QSAR. Fundamentals and applications in chemistry and biology, vol 2. American Chemical Society, Washington, DC.
232. Kubinyi H (1993a) QSAR: Hansch analysis and related approaches. VCH, Weinheim.
233. Kubinyi H (ed) (1993b) 3D-QSAR in drug design: Theory, methods, and applications. ESCOM, Leiden.
234. Kubinyi H, Folkers G, Martin YC (1998) 3D QSAR in drug design, vol 2 and 3. Kluwer/ESCOM, Dordrecht/Boston/London.
235. Ramsden CA (1990) Quantitative drug design. In: Hansch C, Sammes PG, Taylor JB (eds) Comprehensive medicinal chemistry, vol 4. Pergamon Press, Oxford.
236. van de Waterbeemd H (1995a) Chemometric methods in molecular design. VCH, Weinheim.
237. van de Waterbeemd H (1995b) Advanced computer-assisted techniques in drug discovery. VCH, Weinheim.
238. Blaney JM, Hansch C, Silipo C, Vittoria A (1984) Structure-activity relationships of dihydrofolate reductase inhibitors. Chem Rev 84:333-407.
239. Cramer RD, Patterson DE, Bunce JD (1988) Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 110:5959-5967.
240. DePriest SA, Mayer D, Naylor CB, Marshall GR (1993) 3DQSAR of angiotensin-converting enzyme and thermolysin inhibitors: A comparison of CoMFA models based on deduced and experimentally determined active site geometries. J Am Chem Soc 115:5372-5384.
241. Gohlke H, Klebe G (2002) DrugScore meets CoMFA: Adaptation of fields for molecular comparison (AFMoC) or how to tailor knowledge-based pair-potentials to a particular protein. J Med Chem 45:4153-4170.
242. Goodford PJ (1985) A computational procedure of determining energetically favorable binding sites on biologically important macromolecules. J Med Chem 28:849-857.
243. Hansch C, Klein TE (1991) Quantitative structure-activity relationships and molecular graphics in evaluation of enzyme-ligand interactions. Methods Enzymol 202:512-543.
244. Hillebrecht A, Klebe G (2008) The use of 3D QSAR models for database screening: A feasibility study. J Chem Inf Model 48:384-396.
245. Hillebrecht A, Supuran CT, Klebe G (2006) Integrated approach using protein and ligand information to analyze affinity and selectivity determining features of carbonic anhydrase isozymes. ChemMedChem 1:839-853.
246. Kellogg GE, Abraham DJ (1992) Key, lock and locksmith: complementary hydrophathic map predictions of drug structure from a known receptor-receptor structure from known drugs. J Mol Graph 10:212-217.
247. Klebe G, Abraham U, Mietzner T (1994) Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem 37:4130-4146.
248. Ortiz AR, Pisabarro MT, Gago F, Wade RC (1995) Prediction of drug binding affinities by comparative binding energy analysis. J Med Chem 38:2681-2691.
249. Unger SH, Hansch C (1973) On model building in structure-activity relationships. A reexamination of adrenergic blocking activity of b-Halo-b-arylalkylamines. J Med Chem 16:745-749.
250. Weber A, Böhm M, Supuran CT, Scozzafava A, Sotriffer CA, Klebe G (2006) 3D QSAR selectivity analyses of carbonic anhydrase inhibitors: Insights for the design of isozyme selective inhibitors. J Chem Inf Model 46:2737-2760.
251. Dearden JC (1990) Molecular structure and drug transport. In: Ramsden CA (ed) Quantitative drug design, Band 4 von: comprehensive medicinal chemistry, Hansch C, Sammes PG, Taylor JB (eds) Pergamon Press, Oxford, pp 375-411.
252. Hansch C, Leo A (1995) Exploring QSAR. Fundamentals and applications in chemistry and biology, 1st edn. American Chemical Society, Washington, DC.
253. Kubinyi H (1979) Lipophilicity and drug activity. Prog Drug Res 23:97-198.
254. Kubinyi H (1993) QSAR: Hansch analysis and related approaches. Wiley VCH, Weinheim.
255. Lipnick RL (1990) Selectivity. In: Kennewell PD (eds) General principles, vol 1 from: Hansch C, Sammes PG, Taylor JB (eds) Comprehensive medicinal chemistry, Pergamon Press, Oxford, S. 239-247.
256. Mannhold R (ed) (2008) Molecular drug properties. Wiley-VCH, Weinheim.
257. Mayer JM, van de Waterbeemd H (1985) Development of quantitative structure-pharmacokinetic relationships. Environ Health Perspect 61:295-306.
258. Reinhardt CA (ed) (1994) Alternatives to animal testing. Wiley VCH, Weinheim.
259. Seydel JK, Schaper K-J (1982) Quantitative structure-pharmacokinetic relationships and drug design. Pharmacol Ther 15:131-182.
260. Smith DA, van de Waterbeemd H, Walker DK (2006) Pharmacokinetics and metabolism in drug design. Wiley-VCH, Weinheim.
261. Testa B, van de Waterbeemd H (2007) ADME-Tox approaches, vol 5 of comprehensive medicinal chemistry II. Elsevier, Oxford.
262. Clozel J-P, Fischli W (1993) Discovery of Remikiren as the first orally active renin inhibitor. Arzneim-Forsch 43:260-262.
263. Dhanaraj V et al (1992) X-Ray analyses of peptide-inhibitor complexes define the structural basis of specificity for human and mouse renins. Nature 357:466-472.
264. Gitter BD et al (1991) Species differences in affinities of non-peptide antagonists for substance P receptors. Eur J Pharmacol 197:237-238.
265. Hansch C, Björkroth JP, Leo A (1987) Hydrophobicity and central nervous system agents: On the principle of minimal hydrophobicity in drug design. J Pharm Sci 76:663-687.
266. Hanson DJ (1991) Dioxin toxicity: New studies prompt debate, regulatory action. Chem Eng News 69:7-14.
267. Kubinyi H (1978) Drug partitioning: relationships between forward and reverse rate constants and partition coefficient. J Pharm Sci 67:262-263.
268. Lippold BC, Schneider GF (1974) Zur Optimierung der Verfügbarkeit homologer quartärer Ammoniumverbindungen, 2. Mitteilung: In-vitro-Versuche zur Verteilung von Benzilsäureestern homologer Dimethyl-(2-hydroxyäthyl)-alkylammoniumbromide. Arzneim- Forsch 25:843-852.
269. Matfield MJ (1991) Animal liberation or animal research? Trends Pharmacol Sci 12:411-415.
270. Parker EM, Grisel DA, Iben LG, Shapiro RS (1993) A single amino acid difference accounts for the pharmacological distinctions between the rat and human 5-hydroxytryptamine-1B receptors. J Neurochem 60:380-383.
271. Seeman P, Van Tol HHM (1994) Dopamine receptor pharmacology. Trends Pharmacol Sci 15:264-270.
272. Tsuji A, Miyamoto E, Hashimoto N, Yamana T (1978) GI absorption of β-Lactam antibiotics II: deviation from pH-partition hypothesis in penicillin absorption through In Situ and In Vitro lipoidal barriers. J Pharm Sci 67:1705-1711.
273. van de Waterbeemd H, Kansy M (1992) Hydrogen-bonding capacity and brain penetration. Chimia 46:299-303.
274. van de Waterbeemd H, van Bakel P, Jansen A (1981) Transport in quantitative structure-activity relationships VI: relationship between transport rate constants and partition coefficients. J Pharm Sci 70:1081-1082.
275. Beddell CR (ed) (1992) The design of drugs to macromolecular targets. Wiley, Chichester.
276. Böhm HJ, Schneider G (2006) Molecular recognition in protein-ligand interactions. In: Mannhold R, Kubinyi H, Folkers G (eds) Methods and principles in medicinal chemistry, vol 19. Wiley-VCH, Weinheim.
277. Böhm HJ (1993) Ligand design. In: Kubinyi H (ed) 3D QSAR in drug design. Leiden, Escom, pp 386-405.
278. Borman S (1992) New 3-D search and de novo design techniques aid drug development. Chem Eng News 10:18-26.
279. Branden C, Tooze J (1999) Introduction to protein structure, 2nd edn. Garland, New York.
280. Goodford P (1984) Drug design by the method of receptor fit. J Med Chem 27:557-564.
281. Greer J, Erickson JW, Baldwin JJ, Varney MD (1994) Application of the three-dimensional structures of protein target molecules in structure-based drug design. J Med Chem 37:1035-1054.
282. Hubbard TJP, Lesk AM (1995) Modelling protein structures. In: Goodfellow JM (ed) Computer modelling in molecular biology. Weinheim, VCH.
283. Hutchins C, Greer J (1991) Comparative modeling of proteins in the design of novel renin inhibitors. Crit Rev Biochem Molec Biol 26:77-127.
284. Kuntz ID, Meng EC, Shoichet BK (1994) Structure-based molecular design. Acc Chem Res 27:117-123.
285. Kuntz ID (1992) Structure-based strategies for drug design and discovery. Science 257:1078-1082.
286. Martin YC (1992) 3D database searching in drug design. J Med Chem 35:2145-2154.
287. Müller K (1995) De novo design. In: Anderson PS, Kenyon GL, Marshall GR (eds) Persp drug discovery and de-sign, vol 3. Escom, Leiden.
288. Schneider G, Baringhaus KH (2008) Molecular design. Wiley-VCH, Weinheim.
289. Böhm HJ (1992a) LUDI: rule-based automatic design of new substituents for enzyme inhibitor leads. J Comp-Aided Molec Des 6:593-606.
290. Böhm HJ (1992b) The computer program Ludi: A new method for the de novo design of enzyme inhibitors. J Comp-Aided Molec Des 6:61-78.
291. Henderson R, Baldwin JM, Ceska TA, Zemlin F, Beckmann E, Downing KH (1990) Model of the structure of bacteriorhodopsin based on high-resolution electron cryo-microscopy. J Mol Biol 213:899-929.
292. Hibert M, Trumpp-Kallmeyer S, Hoflack J, Bruinvels A (1993) This is not a G-protein-coupled receptor. Trends Pharm Sci 14:7-12.
293. Hoflack J, Trumpp-Kallmeyer S, Hibert M (1994) Re-evaluation of bacteriorhodopsin as a model for G-protein-coupled receptors. Trends Pharm Sci 15:7-9.
294. Overington J, Johnson MS, Sali A, Blundell TL (1990) Tertiary structural constraints on protein evolutionary diversity: Templates, key residues and structure prediction. Proc Roy Soc Lond B 241:132-145.
295. Ring CS et al (1993) Structure-based inhibitor design by using protein models for the development of antiparasitic agents. Proc Natl Acad Sci 90:3583-3587.
296. Sali A, Blundell TL (1990) Definition of general topological equivalence in protein structures. J Mol Biol 212:403-428.
297. Schertler GFX, Villa C, Henderson R (1993) Projection structure of Rhodopsin. Nature 362:770-772.
298. Travis J (1993) Proteins and organic solvents make an eye-opening mix. Science 262:1374.
299. Brenk R, Naerum L, Grädler U, Gerber H-D, Garcia GA, Reuter K, Stubbs MT, Klebe G (2003) Virtual screening for submicromolar leads of TGT based on a new unexpected binding mode detected by crystal structure analysis. J Med Chem 46:1133-1143.
300. Grädler U, Gerber H-D, Goodenough-Lashua DAM, Garcia GA, Ficner R, Reuter K, Stubbs MT, Klebe G (2001) A new target for shigellosis: rational design and crystallographic studies of inhibitors of tRNA-guanine transglycosylase. J Mol Biol 306:455-467.
301. Hörtner S, Ritschel T, Stengl B, Kramer Ch, Klebe G, Diederich F (2007) Design, synthesis, and biological evaluation of inhibitors of tRNA-guanine transglycosylase, an enzyme linked to the pathogenicity of the Shigella bacterium. Angew Chem Int Ed 46:8266-8269.
302. Meyer EA, Brenk R, Castellano RK, Furler M, Klebe G, Diederich F (2002) De Novo design, synthesis, and in vitro evaluation of inhibitors for prokaryotic tRNA-guanine transglycosylase (TGT): A dramatic sulfur effect on binding affinity. Chembiochem 2:250-253.
303. Ritschel T, Hoertner S, Heine A, Diederich F, Klebe G (2009a) Crystal structure analysis and in-silico pKa calculations suggest strong pKa shifts of ligands as driving force for high affinity binding to TGT. Chembiochem 10:716-727.
304. Ritschel T, Kohler PC, Neudert G, Heine A, Diederich F, Klebe G (2009b) How to replace the residual solvation shell of polar active-site residues to achieve nanomolar inhibition of tRNAguanine transglycosylase. ChemMedChem 4:2012-2023.
305. Stengl B, Reuter K, Klebe G (2005) Mechanism and substrate specificity of tRNA - guanine transglycosylases (TGTs): TRNA modifying enzymes from thee three different kingdoms of life seem to share a common mechanism. Chembiochem 6:1-15.
306. Stengl B, Meyer EA, Heine A, Brenk R, Diederich F, Klebe G (2007) Crystal structures of tRNAguanine transglycosylase (TGT) in complex with novel and potent inhibitors unravel pronounced induced-fit adaptations and suggest dimer formation upon substrate binding. J Mol Biol 370:492-511.
307. Folkers G (1995) Lock and key - A hundred years after, Emil Fischer commemorate symposium. Pharm Acta Helv 69:175-269.
308. Hopkins AL, Groom CR (2002) The druggable genome. Nat Rev Drug Discov 1:727-730.
309. Imming P, Sinning C, Meyer A (2006) Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov 5:821-834.
310. Overington JP, Al-Lazikani B, Hopkins AL (2006) How many drug targets are there? Nat Rev Drug Discov 5:993-996.
311. The journals: Trends in Pharmacological Sciences, Chemistry & Biology, Nature Reviews Drug Discovery or Pharmazie in unserer Zeit contain in each edition a highly topical article about the mode of action of a biologically active substance.
312. Austin DJ, Crabtree R, Schreiber SL (1994) Proximity versus allostery: The role of regulated protein dimerization in biology. Chem Biol 1:131-136.
313. Hayes JD, Wolf CR (1990) Molecular mechanisms of drug resistance. Biochem J 272:281-295.
314. Rawlings ND, Morton FR, Barrett AJ (2006) MEROPS: The peptidase database. Nucleic Acids Res 34:D270-D272, http://merops.sanger.ac.uk/.
315. Saudou F, Hen R (1994) 5-HT receptor subtypes: Molecular and functional diversity. Med Chem Res 4:16-84.
316. Westkaemper RB (1993) Serotonin receptors: Molecular genetics and molecular modeling. Med Chem Res 3:269-272.
317. Abbenante G, Fairlie DP (2005) Protease inhibitors in the clinic. Med Chem 1:71-104.
318. Babine RE, Bender SL (1997) Molecular recognition of protein-ligand complexes: Applications to drug design. Chem Rev 97:1359-1472.
319. Berliner LJ (ed) (1992) Thrombin: Structure and function. Plenum, New York.
320. Branden C, Tooze J (1991) Introduction to protein structure. Garland, New York.
321. Kimball SD (1995) Challenges in the development of orally bioavailable thrombin active site inhibitors. Blood Coagul Fibrinolysis 6:511-519.
322. Shafer JA, Gould RJ (eds) (1994) Design of antithrombotic agents, vol 1, Perspectives in drug discovery and design. ESCOM Science Publishers, Leiden, pp 419-550.
323. Steinmetzer T, Stürzebecher J (2004) Progress in the development of synthetic thrombin inhibitors as new orally active anticoagulants. Curr Med Chem 11:2297-2321.
324. Türk B (2006) Targeting proteases: Sucesses, failures and future prospects. Nat Rev Drug Discov 5:785-799.
325. Gustafsson D, Bylund R et al (2004) A new oral anticoagulant: The 50-year challenge. Nat Rev Drug Discov 3:649-659.
326. Hilpert K, Ackermann J, Banner DW, Gast A, Gubernator K, Hadvary P, Labler L, Müller K, Schmid G, Tschopp TB, van de Waterbeemd H (1994) Design and synthesis of potent and highly selective thrombin inhibitors. J Med Chem 37:3889-3901.
327. Veale CA, Bernstein PR, Bryant C et al (1995) Nonpeptidic inhibitors of human leukocyte elastase 5 design, synthesis, and x-ray crystallography of a series of orally active 5- Aminopyrimidin-6- one-containing trifluorormethyl ketones. J Med Chem 38:98-108.
328. Anderson PS, Kenyon GL, Marshall GR (eds) (1993) Therapeutic approaches to HIV, vol 1, Perspectives in drug discovery design. Escom, Leiden.
329. Babine RE, Bender SL (1997) Molecular recognition of protein-ligand complexes: Applications to drug design. Chem Rev 97:1359-1472.
330. Dash C, Kulkarni A, Dunn B, Rao M (2003) Aspartic peptidase inhibitors: Implications in drug development. Crit Rev Biochem Mol Biol 38:89-119.
331. De Clercq E (1995) Toward improved anti-HIV chemotherapy: Therapeutic strategies for intervention with HIV infections. J Med Chem 38:2491-2517.
332. de Clercq E (ed) (2011) Antiviral drug strategies, 50th edn, Methods and principles in medicinal chemistry. Wiley-VCH, Weinheim.
333. Eder J, Hommel U, Cumin F, Martoglio B, Gerhartz B (2007) Aspartic proteases in drug discovery. Curr Pharm Des 13:271-285.
334. Ghosh AK (ed) (2010) Aspartic acid proteases as therapeutic targets, vol 45, Methods and principles in medicinal chemistry. Wiley-VCH, Weinheim.
335. Greenlee WJ, Weber AE (1991) Renin inhibitors, drugs. News & Perspectives 4:332-339.
336. Hutchins C, Greer J (1991) Comparative modeling of proteins in the design of novel renin inhibitors. Crit Rev Biochem Mol Biol 26:77-127.
337. Martin JA, Redshaw S, Thomas GJ (1995) Inhibitors of HIV proteinase. Prog Med Chem 32:239-288.
338. Rosenberg SH (1995) Renin inhibitors. Prog Med Chem 32:37-144.
339. West ML, Fairlie DP (1995) Targeting HIV-1 protease: A test for drug-design methodologies. Trends Pharmacol Sci 16:67-74.
340. Blum A, Böttcher J et al (2008) Structure-guided design of C2-symmetric HIV-1 protease inhibitors based on a pyrrolidine scaffold. J Med Chem 51:2078-2087.
341. Condra JH, Schleif WA, Blahy OM et al (1995) In vivo-emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569-571.
342. Güller R et al (1999) Piperidine-renin inhibitors compounds with improved physicochemical properties. Bioorg Med Chem Lett 9:1403-1408.
343. Kleinert HD, Rosenberg SH, Baker WR et al (1992) Discovery of a peptide-based renin inhibitor with oral bioavailability and efficacy. Science 257:1940-1943.
344. Lam PYS, Jadhav PK, Eyermann CJ et al (1994) Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science 263:380-384.
345. Li YC (2007) Inhibition of renin: An updated review of the development of renin inhibitors. Curr Opin Investig Drugs 8:750-757.
346. Vacca JP et al (1994) L-735, 524: An orally bioavailable human immunodeficiency virus type i protease inhibitor. Proc Natl Acad Sci 91:4096-4100.
347. Vara Prasad JVN, Para KS, Lunney EA et al (1994) Novel series of achiral, low molecular weight, and potent hiv-1 protease inhibitors. J Am Chem Soc 116:6989-6990.
348. Wood JM et al (2003) Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 308:698-705.
349. Becket RP, Davidson AH, Drummond AH, Huxley P, Whittaker M (1996) Recent advances in matrix metalloproteinase inhibitor research. Drug Discov Today 1:16-26.
350. Fersht A (1985) Enzyme structure and mechanism. W. H. Freeman, New York, p 416.
351. Rich DH (1990) Peptidase inhibitors. In: Hansch C, Sammes PG, Taylor JB (eds) Comprehensive medicinal chemistry, vol 2, Enzymes & other molecular targets. Pergamon Press, Oxford, pp 391-441.
352. Türk B (2006) Targeting proteases: Successes, failures and future prospects. Nat Rev Drug Discov 5:785-799.
353. Acharya KR, Sturrock ED, Riordan JF, Ehlers MRW (2003) ACE revisited: A new target for structure-based drug design. Nat Rev Drug Discov 2:891-902.
354. Baldwin JJ, Ponticello GS, Anderson PS et al (1989) Thienothiopyran-2-sulfonamides: Novel topically active carbonic anhydrase inhibitors for the treatment of glaucoma. J Med Chem 32:2510-2513.
355. Bertenshaw SR et al (1993) Thiol and hydroxamic acid containing inhibitors of endothelin converting enzyme. Bioorg Med Chem Lett 3:1953-1958.
356. Bertini I, Calderone V, Fragai M, Luchinat C, Maletta M, Yeo KJ (2006) Snapshots of the reaction mechanism of matrix metalloproteinases. Angew Chem Int Ed 45:7952-7955.
357. Borkakoti N, Winkler FK, Williams DH, D'Arcy A, Broadhurst MJ, Brown PA, Johnson WH, Murray EJ (1994) Structure of the catalytic domain of human fibroblast collagenase complexed with an inhibitor. Nat Struct Biol 1:106-110.
358. Cushman DW, Cheung HS, Sabo EF, Ondetti MA (1977) Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids. Biochemistry 16:5484-5491.
359. Hu J, van den Steen PE, Sang Q-XA, Opdenakker G (2007) Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 6:480-498.
360. Jain R, Chen D, White RJ, Patel DV, Yuan Z (2005) Bacterial peptide deformylase inhibitors: A new class of antibacterial agents. Curr Med Chem 12:1607-1621.
361. Matter H, Schudok M (2004) Recent advances in the design of matrix metalloprotease inhibitors. Curr Opin Drug Discov Devel 7:513-535.
362. Matthews BW (1988) Structural basis of the action of thermolysin and related zinc peptidases. Acc Chem Res 21:333-340.
363. Morgan BP, Holland DR, Matthews BW, Bartlett PA (1994) Structure-based design of an inhibitor of the zinc peptidase thermolysin. J Am Chem Soc 116:3251-3260.
364. Porter JR, Beeley NR, Boyce BA et al (1994) Potent and selective inhibitors of gelatinase-A, Hydroxamic acid derivatives. Bioorg Med Chem Lett 4:2741-2746.
365. Rotella DP (2002) Phosphodiesterase 5 inhibitors: current status and potential applications. Nat Rev Drug Discov 1:674-682.
366. Supuran CT, Scozzafava A (2000) Carbonic anhydrase inhibitors and their therapeutic potential. Expert Opin Ther Pat 10:575-600.
367. Supuran CT, Mastrolorenzo A, Barbaro G, Scozzafava A (2006) Phosphodiesterase 5 inhibitors - drug design and differentiation based on selectivity, pharmacokinetic and efficacy profiles. Curr Pharm Des 12:3459-3465.
368. Alaimo PJ, Shogren-Knaak MA, Shokat KM (2001) Chemical genetic approaches for the elucidation of signalling pathways. Curr Opin Chem Biol 5:360-367.
369. Bialy L, Waldmann H (2005) Inhibitors of protein tyrosine phosphatases: Next-generation drugs? Angew Chem Int Ed 44:3814-3839.
370. Bonifacio MJ, Palma PN, Almeida L, Soares-da-Silva P (2007) Catechol-O-methyltransferase and its inhibitors in Parkinson's disease. CNS Drug Rev 13:352-379.
371. Bridges AJ (2001) Chemical inhibitors of protein kinases. Chem Rev 101:2541-2571.
372. Cowan-Jacob SW, Guez V et al (2004) Imatinib (STI571) resistance in chronic myelogenous leukemia: Molecular basis of the underlying mechanisms and potential strategies for treatment. Mini Rev Med Chem 4:285-299.
373. Fabian MA, Biggs WH et al (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23:329-336.
374. Klebl BM, Müller G (2005) Second-generation kinase inhibitors. Expert Opin Ther Targets 9:975-993.
375. Klebl B, Müller G, Hamacher M (2011) Protein kinasesas drug targets. In: Mannhold R, Kubinyi H, Folkers G (eds) Methods and principles in medicinal chemistry, vol 49. Wiley, Weinheim.
376. Kubinyi H, Müller G (eds) (2004) Chemogenomics in drug discovery. A medicinal chemistry perspective. Wiley, Weinheim.
377. Lane KT, Beese LS (2006) Structural biology of protein farnesyltransferase and geranylgeranyltransferease type I. J Lipid Res 47:681-699.
378. Strickland CL, Weber PC (1999) Farnesyl protein transferase: A review of structural studies. Curr Opin Drug Discov Devel 2:475-483.
379. Bishop AC, Ubersax JA et al (2000) A chemical switch for inhibitor sensitive alleles of any protein kinase. Nature 407:395-401.
380. Cowan-Jacob SW, Fendrich G et al (2007) Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia. Acta Crystallogr D63:80-93.
381. Lerner C, Masjost B et al (2003) Bisubstrate inhibitors for the enzyme catechol-Omethyltransferase (COMT): Influence of inhibitor preorganization and linker length between the two substrate moieties on binding affinity. Org Biomol Chem 1:42-49.
382. Madhusudan, Akamine P, Xuong N-H, Taylor SS (2002) Crystal structure of a transition state mimic of the catalytic subunit of cAMP-dependent protein kinase. Nat Struct Biol 9:273-277.
383. Meggers E, Atilla-Gokcumen GE et al (2007) Exploring chemical space with organometallics: ruthenium complexes as protein kinase inhibitors. Synlett 8:1177-1189.
384. Puius YA et al (1997) Identification of a second aryl phosphate-binding site in protein-tyrosine phosphatase 1B: A paradigm for inhibitor design. Proc Natl Acad Sci U S A 94:13420-13425.
385. Szczepankiewicz BG et al (2003) Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy. J Am Chem Soc 125:4087-4096.
386. Vidgren J, Svensson LA, Liljas A (1994) Crystal structure of catechol-O-methyltransferase. Nature 368:354-358.
387. Chan DCN, Anderson AC. Towards species-specific antifolates. Curr Med Chem. 2006;13: 377-98.
388. Endo A. A historical perspective on the discovery of statins. Proc Jpn Acad Ser B. 2010;86: 484-93.
389. Flower RJ. The development of COX-2 inhibitors. Nat Rev Drug Discov. 2003;2:179-91.
390. Gangjee A, Jain HD. Antifolates - past, present and future. Curr Med Chem Anti-Cancer Agents. 2004;4:405-10.
391. Hoffmann F, Maser E. Carbonyl reductases and pluripotent hydroxysteroid dehydrogenases of the short-chain dehydrogenase/reductase superfamily. Drug Metab Rev. 2007;39:87-144.
392. Lamb DC, Waterman MR, Kelly SL, Guengerich FP. Cytochromes P450 and drug discovery. Curr Opin Biotechnol. 2007;18:504-12.
393. Michaux C, Charlier C. Structural approaches for COX-2 inhibition. Mini Rev Med Chem. 2004;4:603-15.
394. Mitchell JA, Warner TD. COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. Nat Rev Drug Discov. 2006;5:75-86.
395. Oates P. Aldose reductase, still a compelling target for diabetic neuropathy. Curr Drug Targets. 2008;9:14-36.
396. Tobert JA. Lovastatin and beyond: The history of HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003;2:517-26.
397. Vagelos PR. Are prescription drug prices high? Science. 1991;252:1080-4.
398. Webster SP, Pallin TD. 11b-Hydroxysteroid dehydrogenase type 1 inhibitors as therapeutic agents. Expert Opin Ther Patents. 2007;17:1407-22.
399. Weinshilboum R, Wang L. Pharmacogenomics: bench to bedside. Nat Rev Drug Discov. 2004;3:739-48.
400. Wienkers LC, Heath TG. Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov. 2005;4:825-33.
401. Xia W, Low PS. Folate-targeted therapies for cancer. J Med Chem. 2010;53:6811-24.
402. Youdim MBH, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci. 2006;7:295-309.
403. Bertilsson L, Lou YQ, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of Debrisoquin and S-Mephenytoin. Clin Pharmacol Ther. 1992;51:388-97.
404. Cody V, Pace J, Chisum K, Rosowsky A. New insights into DHFR interactions: Analysis of Pneumocystis carinii and mouse DHFR complexes with NADPH and two highly potent 5-(o-Carboxy(alkyloxy) trimethoprim derivatives reveals conformational correlations with activity and novel parallel ring stacking interactions. Proteins. 2006;65:959-69.
405. Daly AK. Pharmacogenetics of the cytochromes P450. Curr Top Med Chem. 2004;4:1733-44.
406. De Colibus L, Li M, et al. Three-dimensional structure of human monoamine oxidase (MAO A): relation to the Structure of rat MAO A and human MAO B. PNAS. 2005;102:12684-9.
407. Ekroos M, Sjögren T. Structural basis for ligand promiscuity in cytochrome P450 3A4. PNAS. 2006;103:13682-7.
408. FitzGerald GA. COX-2 and beyond: Approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov. 2003;2:879-90.
409. Istvan ES, Palnitkar M, Buchanan SK, Deisenhofer J. Crystal structure of the catalytic ortion of human HMGCoA reductase: Insights into regulation of activity and catalysis. EMBO J. 2000;19:819-30.
410. Rosowsky A, Forsch RA, Wright JE. Synthesis and in vivo antifolate activity of rotationally restricted aminopterin and methotrexate analogues. J Med Chem. 2004;47:6958-63.
411. Gronemeyer H, Gustafsson J-A, Laudet V (2003) Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov 3:950-964.
412. Moore JT, Collins JL, Pearce KH (2006) The nuclear receptor superfamily and drug discovery. ChemMedChem 1:504-523.
413. Ottow E, Weinmann H (eds) (2008) Nuclear receptors as drug targets. In: Mannhold R, Kubinyi H, Folkers G (eds) Methods and principles in medicinal chemistry, vol 39. Wiley-VCH, Weinheim.
414. Fieser LF, Fieser M (1959) Steroids. Reinhold, New York.
415. Hirschmann R (1991) Medicinal chemistry in the golden age of biology: lessons from steroid and peptide research. Angew Chem Int Ed Engl 30:1278-1301.
416. Jordan VC (2003) Tamoxifen: A most unlikely pioneering medicine. Nat Rev Drug Discov 2:205-213.
417. Owens J (2004) Growing concern for tamoxifen. Nat Rev Drug Discov 3:647.
418. Timsit YE, Negishi M (2007) CAR and PXR: The xenobiotic-sensing receptors. Steroids 72:231-246.
419. Willson TM, Kliewer SA (2002) PXR, CAR and drug metabolism. Nat Rev Drug Discov 1:259-266.
420. Buck LB (2005) Unraveling the sense of smell (Nobel lecture). Angew Chem Int Ed Engl 44:6128-6140.
421. Martin YC et al (1991) Molecular modeling-based design of novel, selective, potent D1 dopamine agonists, in QSAR: rational approaches to the design of bioactive compounds. Elsevier, Amsterdam, pp 469-482.
422. Rexler RR et al (1996) Nonpeptide angiotensin II receptor antagonists: The next generation in antihypertensive therapy. J Med Chem 39:625-656.
423. Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF (1991) Nonpeptide angiotensin II receptor antagonists. Trends Pharmacol Sci 12:55-61.
424. Bianco R et al (2007) Rational bases for the development of EGFR inhibitors or cancer treatment. Int J Biochem Cell Biol 39:1416-1431.
425. Cherezov V et al (2007) High-resolution crystal structure of an engineered human β2-adrenergic G protein-coupled receptor. Science 318:1258-1265.
426. Copeland RA, Pompliano DL, Meek TD (2007) Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov 5:730-739.
427. De Meyts P, Whittaker J (2002) Structural biology of insulin and IGF1 receptors: Implications for drug design. Nat Rev Drug Discov 1:769-783.
428. Eklind-Cervenka M, Benson L et al (2011) Association of Candesartan vs. Losartan With All-Cause Mortality in Patients With Heart failure. J Am Med Assoc 305:175-182.
429. Ji H, Zheng W, Zhang Y, Catt KJ, Sandberg K (1995) Genetic transfer of a nonpeptidic antagonist binding site to a previously unresponsive angiotensin receptor. Proc Natl Acad Sci USA 92:9240-9244.
430. Keller A, Zhuang H, Chi Q, Vosshall LB, Matsunami H (2007) Genetic variations in a human odorant receptor alters odour preception. Nature 449:468-472.
431. Rasmussen SG et al (2007) Crystal structure of the human β2 adrenergic G-protein coupled receptor. Nature 450:383-387.
432. Rosenbaum DM, Cherezov V et al (2007) GPCR engineering yields high-resolution structural insights into β2-adrenergic receptor function. Science 318:1266-1273.
433. Standfuss J, Edwards PC et al (2011) The structural basis of agonist-induced activation in constitutively active rhodopsin. Nature 471:656-661.
434. Timmermans PBMWM et al (1993) Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 45:205-242.
435. Warne T, Serrano-Vega MJ et al (2008) Structure of a β1-adrenergic G-protein-coupled receptor. Nature 454:486-491.
436. Warne T, Moukhametzianov R et al (2011) The structural basis for agonist and partial agonist action on a β1-adrenergic receptor. Nature 469:241-245.
437. Wu B, Chien EYT et al (2011) Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonist. Science 330:1066-1071.
438. Cascio M (2006) Modulating inhibitory ligand-gated ion channels. AAPS J 8:E353-E361.
439. Higgins C (2007) Multiple molecular mechanisms for multidrug resistance transporters. Nature 446:749-757.
440. MacKinnon R (2003) Nobel lecture, potassium channels and the atomic basis of selective ion conduction, Accessed on 6 June 2012 from http://nobelprize.org/nobel-prizes/chemistry/laureates/2003/mackinnon-lecture.html.
441. Sanguinetti MC, Mitcheson JS (2005) Predicting drug-hERG channel interactions that cause acquired long-QT Syndrome. Trends Pharmacol Sci 26:119-124.
442. Sather WA, McCleskey EW (2003) Permeation and selectivity in calcium channels. Ann Rev Physiol 65:133-159.
443. Sui H, Han BG, Lee JK, Walian P, Jap BK (2001) Structural basis of water-specific transport through the AQP1 water channel. Nature 414:872-878.
444. Triggle DJ, Gopalakrishnan M, Rampe D, Zheng W (2006) Voltage-gated ion channels as drug targets. In: Mannhold R, Kubinyi H, Folkers G (eds) Methods and principles in medicinal chemistry, vol 29. Wiley, Weinheim.
445. Unwin N (1993) Nicotinic acetylcholine receptor at 9 A resolution. J Mol Biol 229:1101-1124.
446. Unwin N (1995) Acetylcholine receptor channel imaged in the open state. Nature 373:37-43.
447. Unwin N (2003) Structure and action of the nicotinic acetylcholine receptor explored by electron microscopy. FEBS Lett 555:91-95.
448. Vaz J, Klabunde T (ed) (2008) Antitargets. Prediction and prevention of drug side effects In: Mannhold R, Kubinyi H, Folkers G (eds) Methods and principles in medicinal chemistry, vol 38. Wiley, Weinheim.
449. Doyle DA, Cabral JM, Pfuetzner RA, Kuo A, Gulbis JM, Cohen SL, Chait BT, MacKinnon R (1998) The structure of the potassium channel: Molecular basis of K+ conduction and selectivity. Science 280:69-77.
450. Dutzler R (2004) Structural basis for ion conduction and gating in ClC chloride channels. FEBS Lett 564:229-233.
451. Shi N, Ye S et al (2006) Atomic structure of a Na+- And K+-conducting channel. Nature 440:570-574.
452. Andronati SA, Karaseva TL, Krysko AA (2004) Peptidomimetics- Antagonists of the fibrinogen receptors: Molecular design, structures, properties and therapeutic applications. Curr Med Chem 11:1183-1211.
453. Chhabra SR, Abdul Rahim AS, Kellam B (2003) Recent progress in the design of selectin inhibitors. Mini Rev Med Chem 3:679-687.
454. De Palma AM, Vliegen I, De Clercq E, Neyts J (2008) Selective inhibitors of picornavirus replication. Med Res Rev 28:823-884.
455. Doranz BJ, Baik SW, Doms RW (1999) Use of a gp120 binding assay to dissect the requirements and kinetics of human immunodeficiency virus fusion events. J Virol 12:10346-10358.
456. Kolata G (2001) The story of the great influenza pandemic of 1918 and the search for the virus that caused it. Touchstone, New York.
457. Lazoura E, Apostolopoulos V (2005) Rational peptide-based vaccine design for cancer immunotherapeutic applications. Curr Med Chem 12:629-639.
458. Matthews T, Salgo M et al (2004) Enfuvirtide: The first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat Rev Drug Discov 3:215-225.
459. Shimaoka M, Springer TA (2003) Therapeutic antagonists and conformational regulation of integrin function. Nat Rev Drug Discov 2:703-716.
460. Somers WS, Tang J, Shaw GD, Camphausen RT (2000) Insights into the molecular basis of leukocyte tethering and rolling revealed by structures of P- And E-selectin bound to SLeX and PSGL-1. Cell 103:467-479.
461. von Itzstein M (2007) The war against influenza: discovery and development of sialidase inhibitors. Nat Rev Drug Discov 6:967-974.
462. Douat-Casassus C, Marchand-Geneste N, Diez E, Gervois N, Jotereau F, Quideau S (2007) Synthetic anticancer vaccine candidates: rational design of antigenic peptide mimetics that activate tumor-specific T-cells. J Med Chem 50:1598-1609.
463. Garboczi DN et al (1996) Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 384:134-141.
464. Jiang S, Zhao Q, Debnath AK (2002) Peptide and non-peptide HIV fusion inhibitors. Curr Pharm Des 8:563-580.
465. Kim CU, Lew W et al (1997) Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc 119:681-690.
466. Kim CU, Lew W et al (1998) Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors. J Med Chem 41:2451-2460.
467. Kolatkar PR et al (1999) Structural studies of two rhinovirus serotypes complexed with fragments of their cellular receptor. EMBO J 18:6249-6259.
468. Kranich R, Busemann AS et al (2007) Rational design of novel, potent small molecule pan-selectin antagonists. J Med Chem 50:1101-1115.
469. Ku TW, Ali FE, Barton LS et al (1993) Direct design of a potent non-peptide fibrinogen receptor antagonist based on the structure and conformation of a highly constrained cyclic RGD peptide. J Am Chem Soc 115:8861-8862.
470. Smith PW, Sollis SL et al (1996) Novel inhibitors of influenza silaidases related to GGI67. Bioorg Med Chem Lett 6:2931-2936.
471. Williams MA, Lew W et al (1997) Structure-activity relationships of carbocyclic influenza neuraminidase inhibitors. Bioorg Med Chem Lett 7:1837-1842.
472. Zablocki JA, Rico JG, Garland RB, Zablocki JA, Rico JG, Garland RB et al (1995) Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp sequence of fibrinogen. (Aminobenzamidino)succinyl (ABAS) series of orally active fibrinogen receptor antagonists. J Med Chem 38:2378-2394.
473. Zhang Y et al (2004) Structural and virological studies of the stages of virus replication that are affected by antirhinovirus compounds. J Virol 78:11061-11069.
474. Aboul-Fadl T (2005) Antisense oligonucleotides: The state of the art. Curr Med Chem 12:2193-2214.
475. Banting A (2004) The bittersweet science. In: Pinker S (ed), Folker T (Series ed) The New York Times Magazine, 16 Mar 2003 or in The best American science and nature writing 2004, Houghtom Mifflin Company.
476. Brekke OH, Sandlie I (2003) Therapeutic antibodies for human diseases at the dawn of the twenty first century. Nat Rev Drug Discov 2:52-62.
477. Das K, Lewi PJ, Hughes SH, Arnold E (2005) Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of nonnucleoside HIV-1 reverse transcriptase inhibitors. Prog Biophys Mol Biol 88:209-231.
478. Dürfahrt T, Marahiel MA (2005) Peptidantibiotika vom molekularen Fließband. Nachr Chem 53:507-513.
479. Kurreck J (2003) Antisense technologies: Improvement through novel chemical modifications. Eur J Biochem 270:1628-1644.
480. Milenic DE, Brady ED, Brechbiel MW (2004) Antibody-targeted radiation therapy. Nat Rev Drug Discov 3:488-498.
481. Poehlsgaard J, Douthwaite S (2005) The bacterial ribosome as a target for antibiotics. Nat Rev Microbiol 3:870-881.
482. Vivet-Boudou V, Didierjean J, Isel C, Marquet R (2006) Nucloside and nucleotide inhibitors of HIV-1 replication. Cell Mol Life Sci 63:163-186.
483. Yonath A, Bashan A (2004) Ribosomal crystallography: Initiation, peptide bond formation, and amino acid polymerization are hampered by antibiotics. Annu Rev Microbiol 58:233-251.
484. Graham J, Muhsin M, Kirkpatrick P (2004) Cetuximab. Nat Rev Drug Discov 3:549-550.
485. Hansen JL, Ippolito JA et al (2002) The structures of four macrolide antibiotics bound to the large ribosomal subunit. Mol Cell 10:117-128.
486. Harms JM, Schlünzen F, Fucini P, Bartels H, Yonath A (2004) Alterations at the peptidyl transferase centre of the ribosome induced by the synergistic action of the streptogramins dalfopristin and quinupristin. BMC Biol 2:4.
487. Laponogov I, Sohi MK et al (2009) Structural insights into the quinolone-DNA cleavage complex of type II topoisomerase. Nat Struct Mol Biol 16:667-669.
488. Saenger W et al (2000) The tetracycline repressor-a paradigm for a biological switch, Angew. Chem Int Ed 39:2042-2052.
489. Schlünzen F, Zarivach R et al (2001) Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature 413:814-821.